Drug Trial Radar · NCT07689188
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Sep 10, 2026
Primary completion
Mar 10, 2028
Study completion Dec 10, 2028
Sponsor
- Lead sponsor
- Harrison DermatologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates the efficacy of topical roflumilast foam in patients with HS.
Conditions
- Hidradenitis Suppurativa (HS)
Interventions
Roflumilast 0.3% topical foamDrug
Roflumilast 0.3% topical foam applied once daily (QD) to all active hidradenitis suppurativa lesions for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16Time frame: Baseline and Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harrison Institute for Clinical Research at Harrison Dermatology
Missouri City, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.